---
title: "Instylla’s Embrace HES gains US FDA premarket approval"
date: "2025-08-07T13:15:11.000Z"
publishedDate: "7 août 2025"
summary: "Instylla has announced premarket approval (PMA) from the US Food and Drug Administration (FDA) for the company’s flagship product Embrace Hydrogel Embolic System (HES). Embrace HES has been approved for the embolization of hypervascular tumours in peripheral arteries ≤5mm."
importance: ""
sourceUrl: "https://interventionalnews.com/instyllas-embrace-hes-gains-us-fda-premarket-approval/"
tags: ["France", "Actualité", "Interventional News — Latest"]
permalink: "/papers/2025-08-07-instyllas-embrace-hes-gains-us-fda-premarket-approval"
imageUrl: "http://interventionalnews.com/wp-content/uploads/sites/13/2025/08/Instylla_Inc_Embrace_FDA_Premarket_Approval.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://interventionalnews.com/instyllas-embrace-hes-gains-us-fda-premarket-approval/"
---

![Instylla’s Embrace HES gains US FDA premarket approval](http://interventionalnews.com/wp-content/uploads/sites/13/2025/08/Instylla_Inc_Embrace_FDA_Premarket_Approval.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://interventionalnews.com/instyllas-embrace-hes-gains-us-fda-premarket-approval/*

## L’essentiel

Instylla has announced premarket approval (PMA) from the US Food and Drug Administration (FDA) for the company’s flagship product Embrace Hydrogel Embolic System (HES). Embrace HES has been approved for the embolization of hypervascular tumours in peripheral arteries ≤5mm.

## Lien source

https://interventionalnews.com/instyllas-embrace-hes-gains-us-fda-premarket-approval/
